Spontaneous proliferative megakaryocytopoiesis and platelet hyperreactivity in essential thrombocythemia: Is thrombopoietin the link?

Annals of Hematology

Volumn 79, Issue 2, 2000, Pages 51-58

  Bellucci, Sylvia ^a   Michiels, Jan Jacques ^b,c  

^a HÔPITAL LARIBOISIÈRE   (France)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Goodheart Institute   (Netherlands)

Author keywords

Essential thrombocythemia; Markers of endothelium activation; Megakaryocytopoiesis; Platelet function; Thrombopoietin

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CELL RECEPTOR; COLLAGEN; COLONY STIMULATING FACTOR; HEPARIN; THROMBIN; THROMBOPOIETIN; WARFARIN;

ARTERY INTIMA; CELL PROLIFERATION; ENDOTHELIUM CELL; GENE MUTATION; HUMAN; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MICROVASCULATURE; MYELOPROLIFERATIVE DISORDER; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REVIEW; STEM CELL; STRUCTURAL GENE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTHEMIA; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 0034069347     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050010     Document Type: Review

References (84)

1. Anagrelide Study Group (1992) Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 92:69-76
2. Axelrad AA, Eskinazi D, Amato D (1998) Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEGrHU-MGDF) in essential thrombocythemia. Blood 92 [Suppl 1]: 488a, 2015A
3. Barbui T, Finazzi G, Dupuy E, Kiladjian JJ, Briere J (1996) Treatment strategies in essential thrombocythemia: a critical appraisal of various experiences in different centers. Leuk Lymphoma 22:149-160
4. Bartley TD, Bogenberger J, Hunt P, et al (1994) Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor mpl. Cell 77:1117-1124
5. Bellucci S (1989) Le syndrome de Moschcowitz. Sang Thromb Vaisseaux 6:359-365
6. Bellucci S, Janvier M, Tobelem G, Flandrin G, Charpak Y, Berger R, Boiron M (1986) Essential thrombocythemias: clinical, evolutionary and biological data. Cancer 58:2440-2447
7. Bellucci S, Ignatova E, Jaillet N, Boffa MC (1993) Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF. Thromb Haemost 70:736-742
8. Berild D, Hasselbalch H, Bjerreknudsen J (1987) Platelet survival, platelet-factor 4 and bleeding time in myeloproliferative disorders. Scand J Clin Lab Invest 47:497-501
9. Boughton BJ, Allington MJ, King A (1978) Platelet and plasma b thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. Br J Haematol 40:125-132
10. Chen J, Herceg-Harjacek L, Groopman JE, Grabarek J (1995) Regulation of platelet activation in vitro by the c-mpl ligand, thrombopoietin. Blood 86:4054-4062
11. Colombi M, Radaelli F, Zocchi L, Maiolo AT (1991) Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 67:2926-2930
12. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556-562
13. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T (1995) Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial. N Engl J Med 332:1132-1136
14. De Sauvage FJ, Hass PE, Spencer SD, et al (1994) Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-mpl ligand. Nature 369:533-538
15. El-Kassar N, Hetet G, Briere J, Grandchamp B (1997) Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood 89:128-134
16. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F (1990) Clinical course of essential thrombocythemia in 147 cases. Cancer 66:549-556
17. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S (1981) Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 58:916-919
18. Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K, De Sauvage FJ (1996) Regulation of thrombopoietin levels by c-mpl mediated binding to platelets.Blood 87:2154-2161
19. Georgii A, Buhr T, Buesche G, Kreft A, Choritz H (1996) Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 22:15-29
20. Greenwalt DE, Lipsky RH, Ockenhouse CF, Ikeda H, Tandon NN, Jamieson GA (1992) Membrane glycoprotein CD36:a review of its roles in adherence, signal transduction, and transfusion medecine. Blood 80:1105-1115
21. Griesshammer M, Bangerter M, Van Vliet HHDM, Michiels JJ (1997) Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Hemost 23:371-378
22. Grossi A, Vannuchi A, Rafanelli D, Filimberti E, Ferrini P (1986) Beta-thromboglobulin content in megakaryocytes of patients with myeloproliferative disorders. Thromb Res 19:367-374
23. Han ZC, Briere J, Abgrall JF, Sensebe L, Nedellec G, Parent D, Guern G (1987) Spontaneous formation of megakaryocyte progenitors (CFU-MK) in primary thrombocythemia. Acta Haematol 78:51-53
24. Han ZC, Bellucci S, Tenza D, Caen JP (1990) Negative regulation of human megakaryocytopoiesis by human platelet factor 4 and beta-thromboglobulin: comparative analysis in bone marrow cultures from normal individuals and patients with essential thrombocythemia and immune thrombocytopenic purpura .Br J Haematol 74:395-401
25. Han ZC, Sensebe L, Abgrall JF, Briere J (1990) Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood 75:1234-1239
26. Han ZC, Maurer AM, Bellucci S, Wan HY, Kroviarski Y, Bertrand O, Caen JP (1992) Inhibitory effect of platelet factor four (PF4) on the growth of human erythroleukemia cells: proposed mechanism of action of PF4. J Lab Clin Med 120:645-660
27. Harrison CN, Gale RE, Wiestner AC, Skoda RC, Linch DC (1998) The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia. Br J Haematol 102:1341-1343
28. Hehlmann R, Jahn M, Baumann B, Kopeke W (1988) Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 61:2487-2496
29. Hirayama Y, Sakamaki S, Matsunaga T, Kuga T, Kuroda H, Kusakabe T, Sasaki K, Fujikawa K, Kato J, Kogawa K, Koyama R, Niitsu Y (1998) Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells. Blood 92:46-52
30. Horikawa Y, Matsumura I, Hashimoto K, Shiraga M, Kosugi S, Tadokoro S, Kato T, Miyazaki H, Tomiyama Y, Kurata Y, Matsuzawa Y, Kanakura Y (1997) Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 90:4031-4038
31. Jabaily J, Hand HJ, Laszlo J. Massey EW, Faguet GB, Briere J, Landaw A, Piciotta AV (1983) Neurologic manifestations of essential thrombocythemia. Ann Intern Med 99:513-518
32. Jacobsson S, Carneskog J, Ridell B, Wadenvik H, Swolin B, Kutti J (1996) Flow cytometric analysis of megakaryocyte ploidy in chronic myeloproliferative disorders and reactive thrombocytosis. Eur J Haematol 56:287-292
33. Juvonen E, Ikkala E, Oksanen K, Ruutu T (1993) Megakaryocyte and erythroid colony formation in essential thrombocythemia and reactive thrombocytosis: diagnostic value and correlation Io complications. Br J Haematol 83:192-197
34. Kiladjian JJ, Elkassar N, Hetet G, Briere J, Grandchamp B, Gardin C (1997) Study of the thrombopoietin receptor in essential thrombocythemia. Leukemia 11:1821-1826
35. Knowles DM, Tolidjian B, Marboe C, D'Agati V, Grimes M, Chess L (1984) Monoclonal anti-human monocyte antibodies OKM1 and OKM5 possess distinctive tissue distributions including differential reactivity with vascular endothelium. J Immunol 132:2170-2173
36. Kobayashi S, Teramura M, Hoshino S, Motoji T, Oshimi K, Mizoguchi H (1993) Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3. Br J Haematol 83:539-544
37. Kondo T, Okabe M, Sanada M, Suzuki S, Kurosawa M, Kobayashi M, Hosokawa M, Asaka M (1997) Identification of TPO gene mutation in familial essential thrombocythemia. Blood 90 [Suppl 1]:54a
38. Koudstaal PJ, Koudstaal A (1997) Neurological and visual disturbances in essential thrombocythemia: efficacy of lowdose aspirin. Semin Thromb Hemost 23:365-370
39. Lahuerta-Palacios JJ, Bornstein R, Fernandez-Debora FJ, et al (1988) Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia. Cancer 61:1207-1212
40. Legrand C, Bellucci S, Disdier M, Edelman L, Tobelem G (1991) Platelet thrombospondin and glycoprotein IV abnormalities in patients with essential thrombocythemia: effect of alpha interferon treatment. Am J Hematol 38:307-313
41. Lengfelder E, Grieshammer M, Hehlmann R (1996) Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 22 [Suppl 1]: 135-142
42. Li J, Xia Y, Kuter DJ (1996) Analysis of the thrombopoietin receptor (Mp1) on platelets from normal and essential thrombocythemic (ET) patients. Blood 88 [Suppl 1]: 545, Abst. 2168
43. Li Y, Hetet G, Kiladjian JJ, Gardin C, Grandchamp B, Briere J (1996) Protooncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders. Br J Haematol 92:60-66
44. Lian EC, Siddiqui FA, Jamieson GA, Tandon NN (1991) Platelet agglutinating protein p37 causes platelet agglutination through its binding to membrane glycoprotein IV. Thromb Haemost 65:102-106
45. Lok S, Kaushansky K, Holly RD, et al (1994) Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369:565-568
46. McGregor JL, Catimel B, Parmentier S, Clezardin P, Dechavanne M, Leung LL (1989) Rapid purification and partial characterization of human platelet glycoprotein IIIb. Interaction with thrombospondin and its role in platelet aggregation. J Biol Chem 264:501-506
47. Metha P, Mehta J, Ross M, Ostrowski N, Player D (1985) Decreased platelet aggregation but increased thromboxane A2 generation in polycythemia vera. Arch Intern Med 145:1225-1227
48. Michiels JJ (1997) Diagnostic criteria of the myeloproliferative disorders (MPD). Neth J Med 51 :57-64
49. Michiels JJ, Juvonen E (1997) Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost 23:339-347
50. Michiels JJ, Ten Kate FWJ (1992) Erythromelalgia in thrombocythemia of various myeloproliferative disorders. Am J Med 39:131-136
51. Michiels JJ, Abels J, Steketee J, Van Vliet HHDM, Vuzevski VD (1985) Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 102:466-471
52. Michiels JJ, Koudstaal PJ, MuldeR AH, Van Vliet HHDM (1993) Transient neurologic ischemic attacks and ocular manifestations in primary thrombocythemia. Neurology 43:1107-1110
53. Michiels JJ, Kutti J, Bazzan M, et al (1999) Diagnosis, pathogenesis and treatment of the myeloproliferative disorders. Neth J Med (in press)
54. Moliterno AR, Hankis D, Spivak JL (1998) Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 338:572-580
55. Najean Y, Poirier O, Lokiec F (1983) The clinical significance of beta-thromboglobulin and platelet factor 4 in polycythaemic patients. Scand J Haematol 31:298-304
56. Preston FE (1983) Aspirin, prostaglandins and peripheral gangrene. Am J Med 74 [Suppl]: 55-60
57. Preston FE, Martin JF, Stewart RM, Davies-Jones GAB (1979) Thrombocytosis, circulating platelet aggregates and neurological dysfunction. Br Med J 2:1561-1563
58. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT (1991) Life expectancy of patients with chronic non-leukemic myeloproliferative disorders. Cancer 67:2658-2663
59. Rocca B, Ciabattoni G, Tartaglione R, Cortelazzo S, Barbui T, Patrono C, Landolfi R (1995) Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 74:1225-1230
60. Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T (1998) No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol 103:772-777
61. Schlemper RJ, Van Der Maas APC, Eikenboom JCJ (1994) Familial essential thrombocythemia: clinical characteristics of 11 cases in one family. Ann Hematol 68:153-158
62. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E, Bordessoule D, Bauters F, Fenaux P (1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 91:616-622
63. Swerlick RA, Lee KH, Wick TM, Lawley TJ (1992) Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol 148:78-83
64. Tandon NN, Rock G, Jamieson GA (1994) Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol 88:816-825
65. Taksin AL, Le Couedic JP, Dusanter-Fourt I, Masse A, Giraudier S, Katz A, Wendung F, Vainchenker W, Casadevall N, Debili N (1999) Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mp1-L. Blood 93:125-139
66. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA (1997) Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, current indications. Semin Thromb Hemost 23:379-383
67. Thibert V, Bellucci S, Cristofari M, Gluckman E, Legrand C (1995) Increased platelet CD36 constitutes a common marker in myeloproliferative disorders. Br J Haematol 91:618-624
68. Thiele J, Kvasnicka HM, Werden C, Zankovich R, Diehl V, Fischer R (1996) Idiopathic primary osteo-myelofibrosis: a clinicopathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognosis impact. Leuk Lymphoma 22:303-317
69. Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels JJ (1999) Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma (in press)
70. Usuki K, Iki S, Endo M, Izutsu K, Inoue K, Nishimura T, Urabe A (1997) Influence of thrombopoietin on platelet activation in myeloproliferative disorders. Br J Haematol 97:530-537
71. Van Genderen PJJ, Michiels JJ (1997) Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 23:357-363
72. Van Genderen PJJ, Michiels JJ, Zijlstra F (1994) Lipoxygenase deficiency in primary thrombocythemia is not a true deficiency. Thromb Haemost 71:803-804
73. Van Genderen PJJ, Michiels JJ, Van Strik R, Lindemans J, Van Vliet HHDM (1995) Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb Haemost 73:210-4
74. Van Genderen PJJ, Budde U, Michiels JJ, Van Strik R, Van Vliet HHDM (1996) The reduction of large von Willebrand factor multimers in plasma in essential thrombocythemia is related to the platelet count. Br J Haematol 93:962-965
75. Van Genderen PJJ, Lucas I, Van Strik R, Vuzevski V, Prins F, Van Vliet H, Michiels JJ (1996) Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost 76:333-8
76. Van Genderen PJJ, Mulder PGH, Waleboer M, Van de Moesdijk D, Michiels JJ (1997) Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 97:179-184
77. Van Genderen PJJ, Prins FJ, Michiels JJ, Schrör K (1999) Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol 104:438-441
78. Von Dem Borne AEGK, Folman C, Linthorst GE, Porcelijn L, Van Den Ouderijn S, Van Der School CE, Haas S (1998) Thrombopoietin and its receptor: structure, function and role in the regulation of platelet production. Acquired disorders of haemostasis. Baillieres Clin Haemotol 11:409-427
79. Von Dem Borne AEGK, Porcelijn L, Folman C, Linthorst GE, Van Den Oudenrijn S, Van Der School CE, Haas S (1998) Thrombopoietin: role in platelet disorders and new drug in clinical medicine. Acquired disorders in haemostasis. Baillieres Clin Haematol 11:427-447
80. Vreeken J, Van Aken WS (1971) Spontaneous aggregation of blood platelets as a cause of idiopathic and recurrent painful toes and fingers. Lancet 2:1394-1397
81. Watson KV, Key N (1993) Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol. 83:198-203
82. Westwood NB, Pearson TC (1996) Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Leuk Lymphoma 22:95-103
83. Wiestner A, Schlemper RJ, Van Der Maas APC, Skoda RC (1998) An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nature Genet 18:49-52
84. Wu KK (1978) Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med 88:7-11